OPEN END TURBO OPTIONSSCHEIN LONG - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 11:56:44 14/06/2024 pm IST | ||
| 25.51 EUR | +1.27% |
|
| Current month | +13.88% | ||
| 1 month | +26.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 25.51 | +1.27% |
| 13/24/13 | 25.19 | +1.70% |
| 12/24/12 | 24.77 | -2.98% |
| 11/24/11 | 25.53 | -0.31% |
| 10/24/10 | 25.61 | +0.04% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 11:56 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GH7GRM |
| ISIN | DE000GH7GRM5 |
| Date issued | 15/06/2021 |
| Strike | 208.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.71 € |
|---|---|
| Lowest since issue | 0.62 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
